Products in this category, I think range anywhere from in the $600 to $800 range. We have not actually priced VEVYE yet, and so that will take — that will happen over the coming months. But as I said, regardless of the price and regardless of the access status, what I can tell you because we will work through the market access issues. We are going to vigorously compete. One of the benefits with the VEVYE transaction is, our cost in acquiring the rights that we have is low relative to the costs for example of other competing companies. And so, that gives us I think some leverage some flexibility in terms of pricing, in terms of rebates and so on. So we are going to compete, we’re going to compete hard. We’re going to try and get as many patients access to what we feel is an extraordinary therapy.
But this is not something that’s going to impact our 2023 revenues. This is a 2024 and really beyond sort of activity. The market is massive. We have an amazing IP estate behind VEVYE. It is an unusual product, the feel of the product, the efficacy. And so, the key for us is that we have it. It’s totally unique. It’s FDA approved. We will work through the access issues and we have a large market and a completely really wide-open playing field, we believe to create value not only for patients, but for our stockholders.
Brooks O’Neil: That’s fantastic. That’s great. So let me just shift gears one more time and then I’ll jump back. TRIESENCE, I think you mentioned in the letter and in your comments, is also a product with enormous potential. My sense is historically one issue has been manufacturability. And I saw in the letter, that you commented that you’ve made some test batches and had some success, but just give us a little more color about the status there and sort of broadly, what you expect the timing to be because my sense is, if you can get that product to be available to your customers is a pretty big market opportunity for you there?
Mark L. Baum: Without question, we’re — we and I said this in the stockholder letter, we’ve had a lot of inbound from ophthalmologists every week, about TRIESENCE. They want it back. They want access to it, for all of the various uses of the product. And you can tell from the stockholder letter that we’ve been doing a lot of work in that regard, with our manufacturing partner. I think the good news is, that the — a batch of the material has been successfully produced. And so what we’re doing now is we’re replicating that, our partner is and we expect that activity to really kind of conclude in the early part of the fourth quarter. And so, we should have some results from these PPQ batches and assuming, those results match the results of the batch that was already successfully produced.
We should have material available to us hopefully, by the end of the year if not in the early part of the first quarter of next year. One final point. The deal that we struck with Novartis, has a financial incentive for them to provide us, with a release of a commercial batch by or before the middle of January. The payment that is owed to Novartis in connection with the NDA transfer for TRIESENCE, is $45 million. However, if the batch is not produced by that time period, so sort of the middle of January the payment that is owed is reduced from $45 million to $37 million. So there’s an $8 million incentive to get this right and to provide us with inventory by the middle of January.
Brooks O’Neil: So will they — just so I understand will they manufacture it for you for a period of time, or are they just helping you and your commercial partner get over the hump of being able to manufacture it?
